ABSTRACT
Consensus-based guidelines supported by the literature are presented on the role of prophylactic administration of factor VIII concentrate in children and adults with severe haemophilia A. The timing of initiation of prophylaxis, the choice of prophylactic regimen, monitoring, management of breakthrough bleeding and education of the patient and family are discussed.
Subject(s)
Coagulants/therapeutic use , Factor VIII/therapeutic use , Hemophilia A/drug therapy , Adult , Child , Drug Monitoring/methods , Evidence-Based Medicine , Hemophilia A/complications , Hemorrhage/etiology , Hemorrhage/prevention & control , Humans , Male , Young AdultSubject(s)
Deamino Arginine Vasopressin/administration & dosage , Hemophilia A/diagnosis , Hemophilia A/therapy , Quality of Life , Combined Modality Therapy , Female , Hemophilia A/mortality , Hemophilia A/nursing , Hemophilia B/diagnosis , Hemophilia B/mortality , Hemophilia B/nursing , Hemophilia B/therapy , Humans , Male , Perioperative Nursing/methods , Preoperative Care/methods , Prognosis , Risk Assessment , Severity of Illness Index , United KingdomABSTRACT
Haemophilia is an inherited disorder of the body's blood clotting mechanism. Past treatments have led to the transmission of blood-borne viruses, primarily HIV and hepatitis C. Current clotting factor concentrates and treatment regimes offer patients a good quality of life. Specialist haemophilia nurses play a pivotal role in the organisation and delivery of care to this patient group.
